First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis-Reference-Cited by-同舟云学术

First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis

Published:2023-05-04 Issue:5 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Aldin Angela¹,Besiroglu Burcu¹,Adams Anne²,Monsef Ina¹,Piechotta Vanessa¹,Tomlinson Eve³,Hornbach Carolin¹,Dressen Nadine¹,Goldkuhle Marius¹,Maisch Philipp⁴,Dahm Philipp⁵,Heidenreich Axel⁶,Skoetz Nicole¹

Affiliation:

1. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

2. Institute of Medical Statistics and Computational Biology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

3. Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK

4. Department of Urology; University of Ulm; Ulm Germany

5. Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA

6. Department of Urology, Uro-oncology, Special Urological and Robot-assisted Surgery; University Hospital of Cologne; Cologne Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference656 articles.

1. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma;Jonasch;Journal of Clinical Oncology. Conference: ASCO Annual Meeting,2007

2. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis;Jonasch;Cancer,2010

3. Atkins MB Hidalgo M Stadler W Logan T Dutcher JP Hudes G A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma Proceedings of the American Society of Clinical Oncology 2002 10a, Abstract 36

4. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features;Bellmunt;Annals of Oncology,2008

5. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC);Hudes;Journal of Clinical Oncology: ASCO Annual Meeting Proceedings,2006

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of metastatic сlear cell renal cell carcinoma: focus on a group of patients with favourable prognosis;Meditsinskiy sovet = Medical Council;2024-01-17

2. Mesenchymal–Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis;International Journal of Molecular Sciences;2023-12-18

3. For adults with advanced renal cell carcinoma, what are the benefits and harms of first-line therapy?;Cochrane Clinical Answers;2023-08-08